148 related articles for article (PubMed ID: 26081639)
1. Ocular and neurodevelopmental features of Duchenne muscular dystrophy: a signature of dystrophin function in the central nervous system.
Ricotti V; Jägle H; Theodorou M; Moore AT; Muntoni F; Thompson DA
Eur J Hum Genet; 2016 Apr; 24(4):562-8. PubMed ID: 26081639
[TBL] [Abstract][Full Text] [Related]
2. Dystrophin gene mutation location and the risk of cognitive impairment in Duchenne muscular dystrophy.
Taylor PJ; Betts GA; Maroulis S; Gilissen C; Pedersen RL; Mowat DR; Johnston HM; Buckley MF
PLoS One; 2010 Jan; 5(1):e8803. PubMed ID: 20098710
[TBL] [Abstract][Full Text] [Related]
3. Learning, memory and blood-brain barrier pathology in Duchenne muscular dystrophy mice lacking Dp427, or Dp427 and Dp140.
Verhaeg M; Adamzek K; van de Vijver D; Putker K; Engelbeen S; Wijnbergen D; Overzier M; Suidgeest E; van der Weerd L; Aartsma-Rus A; van Putten M
Genes Brain Behav; 2024 Jun; 23(3):e12895. PubMed ID: 38837620
[TBL] [Abstract][Full Text] [Related]
4. Emotional behavior and brain anatomy of the mdx52 mouse model of Duchenne muscular dystrophy.
Saoudi A; Zarrouki F; Sebrié C; Izabelle C; Goyenvalle A; Vaillend C
Dis Model Mech; 2021 Sep; 14(9):. PubMed ID: 34546327
[TBL] [Abstract][Full Text] [Related]
5. Red-green color vision impairment in Duchenne muscular dystrophy.
Costa MF; Oliveira AG; Feitosa-Santana C; Zatz M; Ventura DF
Am J Hum Genet; 2007 Jun; 80(6):1064-75. PubMed ID: 17503325
[TBL] [Abstract][Full Text] [Related]
6. The IAAM LTBP4 Haplotype is Protective Against Dystrophin-Deficient Cardiomyopathy.
Bello L; Sabbatini D; Fusto A; Gorgoglione D; Borin GU; Penzo M; Riguzzi P; Villa M; Vianello S; Calore C; Melacini P; Vio R; Barp A; D'Angelo G; Gandossini S; Politano L; Berardinelli A; Messina S; Vita GL; Pedemonte M; Bruno C; Albamonte E; Sansone V; Baranello G; Masson R; Astrea G; D'Amico A; Bertini E; Pane M; Lucibello S; Mercuri E; Spurney C; Clemens P; Morgenroth L; Gordish-Dressman H; McDonald CM; Hoffman EP; ; Pegoraro E
J Neuromuscul Dis; 2024; 11(2):285-297. PubMed ID: 38363615
[TBL] [Abstract][Full Text] [Related]
7. Early Gross Motor Milestones in Duchenne Muscular Dystrophy.
Norcia G; Lucibello S; Coratti G; Onesimo R; Pede E; Ferrantini G; Brogna C; Cicala G; Carnicella S; Forcina N; Fanelli L; Pane M; Mercuri E
J Neuromuscul Dis; 2021; 8(4):453-456. PubMed ID: 33935100
[TBL] [Abstract][Full Text] [Related]
8. Single-transcript multiplex
Hildyard JCW; Crawford AH; Rawson F; Riddell DO; Harron RCM; Piercy RJ
Wellcome Open Res; 2020; 5():76. PubMed ID: 32724863
[No Abstract] [Full Text] [Related]
9. Differential expression of
Alnassar N; Derry JMJ; Banna GL; Gorecki DC
Transl Lung Cancer Res; 2024 Apr; 13(4):733-748. PubMed ID: 38736495
[TBL] [Abstract][Full Text] [Related]
10. Expression of Dystrophin Dp71 Splice Variants Is Temporally Regulated During Rodent Brain Development.
González-Reyes M; Aragón J; Sánchez-Trujillo A; Rodríguez-Martínez G; Duarte K; Eleftheriou E; Barnier JV; Naquin D; Thermes C; Romo-Yáñez J; Roger JE; Rendon A; Vaillend C; Montanez C
Mol Neurobiol; 2024 May; ():. PubMed ID: 38802640
[TBL] [Abstract][Full Text] [Related]
11. Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations.
Ricotti V; Mandy WP; Scoto M; Pane M; Deconinck N; Messina S; Mercuri E; Skuse DH; Muntoni F
Dev Med Child Neurol; 2016 Jan; 58(1):77-84. PubMed ID: 26365034
[TBL] [Abstract][Full Text] [Related]
12. Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy.
Betts CA; Saleh AF; Carr CA; Muses S; Wells KE; Hammond SM; Godfrey C; McClorey G; Woffindale C; Clarke K; Wells DJ; Gait MJ; Wood MJ
Sci Rep; 2015 Jun; 5():11632. PubMed ID: 26113184
[TBL] [Abstract][Full Text] [Related]
13. Non-Invasive Biomarkers for Duchenne Muscular Dystrophy and Carrier Detection.
Anaya-Segura MA; García-Martínez FA; Montes-Almanza LA; Díaz BG; Avila-Ramírez G; Alvarez-Maya I; Coral-Vazquez RM; Mondragón-Terán P; Escobar-Cedillo RE; García-Calderón N; Vazquez-Cardenas NA; García S; López-Hernandez LB
Molecules; 2015 Jun; 20(6):11154-72. PubMed ID: 26091074
[TBL] [Abstract][Full Text] [Related]
14. Quantitative muscle MRI: A powerful surrogate outcome measure in Duchenne muscular dystrophy.
Bonati U; Hafner P; Schädelin S; Schmid M; Naduvilekoot Devasia A; Schroeder J; Zuesli S; Pohlman U; Neuhaus C; Klein A; Sinnreich M; Haas T; Gloor M; Bieri O; Fischmann A; Fischer D
Neuromuscul Disord; 2015 Sep; 25(9):679-85. PubMed ID: 26096788
[TBL] [Abstract][Full Text] [Related]
15. Advances in genetic therapeutic strategies for Duchenne muscular dystrophy.
Guiraud S; Chen H; Burns DT; Davies KE
Exp Physiol; 2015 Dec; 100(12):1458-67. PubMed ID: 26140505
[TBL] [Abstract][Full Text] [Related]
16. Magnetic Resonance Assessment of Hypertrophic and Pseudo-Hypertrophic Changes in Lower Leg Muscles of Boys with Duchenne Muscular Dystrophy and Their Relationship to Functional Measurements.
Vohra RS; Lott D; Mathur S; Senesac C; Deol J; Germain S; Bendixen R; Forbes SC; Sweeney HL; Walter GA; Vandenborne K
PLoS One; 2015; 10(6):e0128915. PubMed ID: 26103164
[TBL] [Abstract][Full Text] [Related]
17. Pathways Implicated in Tadalafil Amelioration of Duchenne Muscular Dystrophy.
De Arcangelis V; Strimpakos G; Gabanella F; Corbi N; Luvisetto S; Magrelli A; Onori A; Passananti C; Pisani C; Rome S; Severini C; Naro F; Mattei E; Di Certo MG; Monaco L
J Cell Physiol; 2016 Jan; 231(1):224-32. PubMed ID: 26097015
[TBL] [Abstract][Full Text] [Related]
18. The Dystrophin Complex: Structure, Function, and Implications for Therapy.
Gao QQ; McNally EM
Compr Physiol; 2015 Jul; 5(3):1223-39. PubMed ID: 26140716
[TBL] [Abstract][Full Text] [Related]
19. Comparative Label-Free Mass Spectrometric Analysis of Mildly versus Severely Affected mdx Mouse Skeletal Muscles Identifies Annexin, Lamin, and Vimentin as Universal Dystrophic Markers.
Holland A; Henry M; Meleady P; Winkler CK; Krautwald M; Brinkmeier H; Ohlendieck K
Molecules; 2015 Jun; 20(6):11317-44. PubMed ID: 26102067
[TBL] [Abstract][Full Text] [Related]
20. A Phase I/IIa Clinical Trial in Duchenne Muscular Dystrophy Using Systemically Delivered Morpholino Antisense Oligomer to Skip Exon 53 (SKIP-NMD).
Hum Gene Ther Clin Dev; 2015 Jun; 26(2):92-5. PubMed ID: 26086759
[No Abstract] [Full Text] [Related]
[Next] [New Search]
